Since endovascular aneurysm repair (EVAR) was introduced by Parodi et al. in 1991 (1), EVAR is widely accepted as the alternative treatment to open repair for abdominal aortic aneurysm (AAA) (2-9) and is available in Korea (10). Although long-term results are not available, several reports have demonstrated the advantages of EVAR including a lower 30-day mortality, reduced operation time, shorter hospital stay, and quicker return to normal activity compared to open repair (4, 6-8). However, 14-66% of AAA patients are eligible for EVAR according to several reports from western countries in terms of morphologic suitability (MS) (11-13). To our knowledge, there has been no study regarding MS in patients with AAA in Korea. This study may be important because improper application against anatomical factors will be related with higher rates of complications and clinical failure, such as endoleak, mesenteric ischemia, or rupture (2, 14, 15). The aim of this study was to examine MS of EVAR with currently available grafts and to obtain basic information to improve the outcome by better patient selection.

We reviewed the computed tomographic angiography (CTA) of 82 patients that had been diagnosed as AAA and were managed medically (7 patients) and surgically (open repair in 66, EVAR in 9) from January 2005 to December 2006 in Seoul National University Hospital and Seoul National University Bundang Hospital. Inclusion criteria of Zenith (Cook Company, Bloomington, IL, U.S.A.) and Excluder (WL Gore, Flagstaff, AZ, U.S.A.) that is available in Korea were adopted to analyze suitability (Fig. 1). Referring to the manufacturer's recommendations, a single observer reviewed the CTA images of each patient and calculated the following numeric data to be required for estimating MS with electronic caliper in PACS (M-View™, Marotech, Seoul, Korea); proximal neck length; proximal neck diameter; maximal diameter of aneurysm; diameter of common iliac and external iliac artery (EIA); diameter of common femoral artery; distal fixation length. The shortest diameter was measured from outer wall to outer wall in Zenith and from inner wall to inner wall in Excluder. Angle was measured as the most severe angle between the longitudinal axis of aneurysm body and proximal aortic neck in 3D reconstruction. Proximal neck length was calculated from the lowest margin of caudal renal artery to the onset of aneurysm considering the slice thickness. Briefly, aortic neck volumetry was performed by manually segregating each single consecutive axial CTA slice between start and stop slices and calculated. Distal fixation length was considered as the length of fixation site deliberating sufficient sealing and the origin of internal iliac artery (IIA). For example, if aneurysm was confined to only the proximal common iliac artery (CIA), EVAR would be eligible in the routine manner. However, if the aneurysm involvement extended to the origin of IIA, endograft limb should be deployed in EIA, which occludes the IIA. The morphologic suitability and the reason for exclusion were examined. The differences between suitable and unsuitable population was analyzed with Students t-test and χ²-test, and Pearson's correlation.

Since EVAR was first introduced by Parodi et al. in 1991 (1), there are some controversies about the therapeutic role of EVAR due to the absence of long-term outcome data (4-6). However, clinical trials of EVAR are increasing worldwide now (2-9). According to the national survey from the Korean society for vascular surgery, most patients were treated by open repair (n=918, 88.6%), and only 11.4% of patients were treated by EVAR from January 2000 to July 2004, but the number of EVAR was increasing (10). Randomized controlled studies have conclusively demonstrated several initial benefits of EVAR compared to open repair in terms of early morbidity and mortality (4, 6). Vogel et al. (8) reported that EVAR groups showed excellent functional scores compared to open repair at the postoperative 3 months. Brewster et al. (9) reported that EVAR had increased rapidly, with 40-50% of all elective AAA patients in U.S.A., and at his institution, 65-70% of infrarenal AAA were recently treated by EVAR. Although early favorable results have broadened the applications of this treatment, the problems specific to EVAR, such as migration or dilation of endograft, endoleak, endotension, and device structural failure resulting in expansion or rupture of aneurysm, are documented in several mid-term results (5, 7, 9, 11, 17). Several reports described that inadequate patient selection for EVAR would cause a higher complication rate as well as long-term re-intervention rate (2, 15). However, stringent inclusion criteria may restrict the widespread adoption of this modern technology. Therefore, morphologic suitability of EVAR varies from 14% to 66%, possibly due to patient selection criteria, the methodology to measure anatomic factors, and the supplemental combination of multiple devices (11-13). Elkouri et al. (11) reported 14% of morphologic suitability with 2 currently available bifurcated endografts and the main reason for exclusion for EVAR was a poor proximal aortic neck. On the contrary, others reported a much higher rate of MS (12). They described that 66% of AAA patients were able to treat EVAR with 6 different types of endografts. They also found that inadequate proximal neck anatomy was the most common reason of exclusion for EVAR: a short proximal neck length (54%), inadequate access because of small iliac arteries (47%), wide neck (40%), bilateral CIA aneurysms extending to IIA (21%). To our knowledge, there were no reports that dealt with MS in Korea. In our study, 39% of MS is among the previously published rates of MS, and the main reason of exclusion for EVAR was the inadequate anatomy of proximal neck similar to other reports. There are some typical features in Asian people, such as a small diameter of Aorta and more frequent iliac aneurysm involvement and calcification. Owing to the anatomical difference of Koreans, such as relatively higher rates (EUROSTAR type C, D, E) (67.1%) of CIA aneurysm, however, the detailed proportions of exclusion in our study may be thought to be different from those of other ethnics. In the dream trial, there were type A in 32 (9.3%), type B in 215 (62.3%), type C in 36 (10.4%), type D in 29 (8.4%), and type E in 33 (9.6%). The CIA involvement rate with AAA was much lower (28.4%) compared with our study. With respect to anatomical features of AAA in Asians, Cheng et al. (18) reported a similar pattern to ours. They described that the CIA length was significantly shorter in Asians (right; 29.9 mm, left; 34.2 mm) than in Caucasians (p<0.001) and CIA diameter was wider (right; 20.2 mm, left; 17.9 mm). Those features might be resulted in one or both IIA exclusion more than 50% of patients. However, Masuda et al. (3) demonstrated that asian ethnics had smaller EIA diameters (p=0.0003) and more tortuous iliac arteries (p=0.03) but CIA diameter, maximal aneurysmal diameter, aortic neck diameter and iliac arterial calcification were not associated with statistically significant differences compared to non-asians in Hawaii. Therefore, it is not clear whether the anatomical difference of Korean may reduce MS of EVAR.

Welborn et al. (19) showed that the aneurysm size is intimately correlated with short neck, steep neck angulation, decreased CIA landing zones and more tortuosity, which should be decreased suitability of EVAR. Ouriel et al. (14) also described that as aneurysm size increased, several morphologic features including aneurysm length, angulation, and iliac artery size might be changed. Our study demonstrated consistent findings similar to above studies. Therefore, it is not surprising that the aneurysm size is a significant factor affecting complications, such as endoleaks or stent migration (2, 20, 21). Gender issues happen to be important in the patient selection for EVAR. Several investigators suggested that disproportionate numbers of women were excluded for EVAR owing to an access problem and small aorta size (8, 12, 17, 22). Additionally, some studies have shown that women had an increased length of hospital stay and need a post-discharge home care system following EVAR compared with men (8). However, their reason is not clearly examined. In our study, gender did not affect the feasibility of EVAR, which might be originated from the small numbers of women. The important prerequisite of clinical success of EVAR in extensive CIA aneurysm is IIA embolization. If CIA aneurysm extends to iliac bifurcation, one should conduct prophylactic iliac embolization to prevent endoleak from backflow of IIA and extend the endograft limb into EIA. However, if there is no blood supply from at least one of IIA, significant co-morbidity, namely pelvic ischemia, will be occurred. Pelvic ischemia can induce mostly buttock claudication, bowel ischemia, sexual dysfunction, and buttock claudication. Therefore, one should be cautious to keep at least one IIA open for bilateral CIA aneurysm, as many investigators have recommended (2, 12). There are several reports that tried to overcome the anatomical unsuitability. The treatment of poor proximal neck problem includes a combination of suprarenal fixation, fenestrated endograft and scallop, hook, or barbs (23, 24). To surmount poor distal fixation problems, several authors have described novel techniques, such as bell bottom technique, hypogastric bypass, or the use of bifurcated endograft into iliac bifurcation, to extend the application of EVAR for both iliac involvements (25, 26). If physicians who dealing with EVAR in Korea will generally adopt this policy, it will be more applicable with good functional outcomes.

In conclusion, when we follow the manufacturer's recommended criteria of 2 currently available endograft in Korea, 46.3% of MS will be feasible. If we stick to preserve at least one internal iliac artery to prevent pelvic ischemia, 39% of MS will be obtained in routine EVAR procedure. More efforts for fine skill and better understanding of stent graft design as well as patient anatomy will result in a higher feasibility in patients with AAA in Korea.